{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:58:30Z","timestamp":1791669510789,"version":"4.3.4"},"reference-count":32,"publisher":"Portland Press Ltd.","issue":"5","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Laryngeal squamous cell carcinoma (LSCC) is a highly disabling disease to the patient, affecting speech, swallowing and respiratory skills. Smoking and alcohol abuse are principal risk factors linked to this disease. Genetic factors can be involved in carcinogenesis by controlling the cell cycle, cell survival, angiogenesis, and invasiveness. Single nucleotide polymorphisms (SNPs) involving specific genes could modulate the risk of LSCC related to known carcinogens by modifying cellular responses, but not all genetic associations are known.<\/jats:p>\n               <jats:p>In a case\u2013control study, we assess the associations between cyclooxygenase-2 (COX2), epidermal growth factor (EGF), EGF receptor (EGFR), and tumor suppressor P53 SNPs on the risk of LSCC development in the Chilean population. A total of 85 LSCC patients and 95 healthy volunteers were recruited. SNPs genotype were analyzed from genomic DNA by Polymerase Chain Reaction (PCR)-Restriction Fragment Length Polymorphism (RFLP) and associations were estimated by odds ratios (ORs) using unconditional logistic regressions.<\/jats:p>\n               <jats:p>A significant association between COX2 and TP53 SNP and LSCC risk was found, with an OR = 3.27 for COX2 c.-1329A&amp;gt;G (rs689466) SNP, and an OR = 1.94 for TP53 c.215C&amp;gt;G, Pro72Arg (rs1042522) SNP. These findings suggest that COX2 c.-1329A&amp;gt;G and TP53 c.215C&amp;gt;G (Pro72Arg) SNPs may be risk factors for LSCC.<\/jats:p>\n               <jats:p>Through this research, we identify two low penetrance genetic variants that may be evaluated as novel biomarkers for this disease, in South American Mestizo populations.<\/jats:p>","DOI":"10.1042\/bsr20191188","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T10:58:51Z","timestamp":1587985131000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Genetic polymorphisms as non-modifiable susceptibility factors to laryngeal cancer"],"prefix":"10.1042","volume":"40","author":[{"given":"Paula","family":"Escalante","sequence":"first","affiliation":[{"name":"Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic-Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile & Latin American Network for the Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Barr\u00eda","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology Service, Barros Luco Hospital, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Cancino","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology Service, Barros Luco Hospital, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maritza","family":"Rahal","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology Service, Barros Luco Hospital, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Cerpa","sequence":"additional","affiliation":[{"name":"Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic-Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile & Latin American Network for the Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sandoval","sequence":"additional","affiliation":[{"name":"Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic-Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile & Latin American Network for the Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Molina-Mellico","sequence":"additional","affiliation":[{"name":"Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic-Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile & Latin American Network for the Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Su\u00e1rez","sequence":"additional","affiliation":[{"name":"Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic-Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile & Latin American Network for the Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic-Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile & Latin American Network for the Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dante Daniel","family":"C\u00e1ceres","sequence":"additional","affiliation":[{"name":"School of Public Health, Faculty of Medicine, University of Chile, Santiago, Chile"},{"name":"Health Science Faculty, Tarapac\u00e1 University, Iquique, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis\u00a0Abel","family":"Qui\u00f1ones","sequence":"additional","affiliation":[{"name":"Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic-Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile & Latin American Network for the Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5229-3007","authenticated-orcid":false,"given":"Nelson\u00a0Miguel","family":"Varela","sequence":"additional","affiliation":[{"name":"Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic-Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile & Latin American Network for the Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"2021111620095702100_B1","volume-title":"Cancer Facts & Figures 2018","author":"American Cancer Society","year":"2018"},{"key":"2021111620095702100_B2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4065\/83.4.489","article-title":"Head and neck cancer: changing epidemiology, diagnosis, and treatment","volume":"83","author":"Marur","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"2021111620095702100_B3","first-page":"108","article-title":"Tumours of the hypopharynx, larynx and trachea","volume-title":"Pathology and Genetics of Head","author":"Barnes","year":"2005"},{"key":"2021111620095702100_B4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/1471-2407-14-187","article-title":"Alcohol consumption, cigarette smoking and the risk of subtypes of head-neck cancer: results from the Netherlands Cohort Study","volume":"14","author":"Maasland","year":"2014","journal-title":"BMC Cancer"},{"key":"2021111620095702100_B5","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/jnci\/91.14.1194","article-title":"Tobacco smoke carcinogens lung cancer","volume":"91","author":"Hecht","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"2021111620095702100_B6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrc2191","article-title":"Molecular mechanisms of alcohol mediated carcinogenesis","volume":"7","author":"Seitz","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"2021111620095702100_B7","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1007\/s11033-014-3125-6","article-title":"Genetic variations and head and neck cancer risks","volume":"41","author":"Masood","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"2021111620095702100_B8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/em.21837","article-title":"Polymorphisms in drug-metabolizing enzymes and risk to head and neck cancer: evidence for gene-gene and gene-environment interaction","volume":"55","author":"Maurya","year":"2014","journal-title":"Environ. Mol. Mutagen."},{"key":"2021111620095702100_B9","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/sj.bjp.0704365","article-title":"COX-2 and cancer: a new approach to an old problem","volume":"134","author":"Bakhle","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"2021111620095702100_B10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1470-2045(03)01220-8","article-title":"Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?","volume":"4","author":"Gasparini","year":"2001","journal-title":"Lancet Oncol."},{"key":"2021111620095702100_B11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1590\/S0004-28032014000200002","article-title":"-765 G&gt;C Polymorphism of the COX-2 gene and gastric cancer risk in Brazilian population","volume":"51","author":"Campanholo","year":"2014","journal-title":"Arq. Gastroenterol."},{"key":"2021111620095702100_B12","first-page":"565","article-title":"Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer","volume":"129","author":"Zhang","year":"2005","journal-title":"Gastroenterology"},{"key":"2021111620095702100_B13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.5009\/gnl.2012.6.3.321","article-title":"The COX-2-1195AA genotype is associated with diffuse-type gastric cancer in Korea","volume":"6","author":"Shin","year":"2012","journal-title":"Gut Liver"},{"key":"2021111620095702100_B14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.mrfmmm.2009.01.007","article-title":"Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squamous cell carcinoma","volume":"663","author":"Upadhyay","year":"2009","journal-title":"Mutat. Res."},{"key":"2021111620095702100_B15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/oxfordjournals.bmb.a072464","article-title":"Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers","volume":"47","author":"Gullick","year":"1991","journal-title":"Br. Med. Bull."},{"key":"2021111620095702100_B16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.semcdb.2014.01.011","article-title":"Epidermal growth factor, from gene organization to bedside","volume":"28","author":"Zeng","year":"2014","journal-title":"Semin. Cell Dev. Biol."},{"key":"2021111620095702100_B17","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.4238\/2015.April.28.10","article-title":"Correlation between P53 and epidermal growth factor receptor expression in breast","volume":"14","author":"Wang","year":"2015","journal-title":"Genet. Mol. Res."},{"key":"2021111620095702100_B18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(02)07600-6","article-title":"Association between functional polymorphism in EGF gene and malignant melanoma","volume":"359","author":"Shahbazi","year":"2002","journal-title":"Lancet"},{"key":"2021111620095702100_B19","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3748\/wjg.v17.i4.488","article-title":"Association between EGF +61A\/G polymorphism and gastric cancer in Caucasians","volume":"17","author":"Ara\u00fajo","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"2021111620095702100_B20","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.2147\/OTT.S70188","article-title":"EGF and EGFR genetic polymorphisms predict prognosis in locally advanced pharyngolaryngeal squamous cell carcinoma patients receiving postoperative concurrent chemoradiotherapy","volume":"7","author":"Su","year":"2014","journal-title":"Onco Targets Ther."},{"key":"2021111620095702100_B21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4103\/1947-2714.109189","article-title":"Allele frequencies of the epidermal growth factor receptors polymorphism R521K in colorectal cancer patients and healthy subjects indicate a risk-reducing effect of K521 in Syrian population","volume":"5","author":"Mustafa","year":"2013","journal-title":"N. Am. J. Med. Sci."},{"key":"2021111620095702100_B22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/ijc.11548","article-title":"P53 polymorphic variants at codon 72 exert different effects on cell cycle progression","volume":"108","author":"Pim","year":"2004","journal-title":"Int. J. Cancer"},{"key":"2021111620095702100_B23","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1128\/MCB.19.2.1092","article-title":"Two polymorphic variants of wild-type P53 differ biochemically and biologically","volume":"19","author":"Thomas","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"2021111620095702100_B24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1593\/neo.12594","article-title":"The P53 codon 72 Pro\/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the P53-72P isoform","volume":"14","author":"Cattelani","year":"2012","journal-title":"Neoplasia"},{"key":"2021111620095702100_B25","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1745-7262.2006.00135.x","article-title":"Joint effect among P53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study","volume":"8","author":"Irarr\u00e1zabal","year":"2006","journal-title":"Asian J. Androl."},{"key":"2021111620095702100_B26","doi-asserted-by":"publisher","first-page":"e34422","DOI":"10.1371\/journal.pone.0034422","article-title":"Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas","volume":"7","author":"Loeb","year":"2012","journal-title":"PLoS ONE"},{"key":"2021111620095702100_B27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(02)07600-6","article-title":"Association between functional polymorphism in EGF gene and malignant melanoma","volume":"359","author":"Shahbazi","year":"2002","journal-title":"Lancet"},{"key":"2021111620095702100_B28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00432-008-0464-5","article-title":"EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer","volume":"135","author":"Sasaki","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2021111620095702100_B29","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.ygyno.2004.11.005","article-title":"Glutathione-S-transferase and p53 polymorphisms in cervical carcinogenesis","volume":"96","author":"Ueda","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"2021111620095702100_B30","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/aje\/153.10.1016","article-title":"Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond","volume":"153","author":"Botto","year":"2001","journal-title":"Am. J. Epidemiol."},{"key":"2021111620095702100_B31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/oxfordjournals.epirev.a017944","article-title":"Evolving methods in genetic epidemiology. III. Gene\u2013environment interaction in epidemiologic research","volume":"19","author":"Yang","year":"1997","journal-title":"Epidemiol. Rev."},{"key":"2021111620095702100_B32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nm0302-289","article-title":"Prostaglandin E2 transactivates EGF-receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy","volume":"8","author":"Pai","year":"2002","journal-title":"Nat. Med."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20191188\/877848\/bsr-2019-1188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20191188\/877848\/bsr-2019-1188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:46:03Z","timestamp":1637095563000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/40\/5\/BSR20191188\/222773\/Genetic-polymorphisms-as-non-modifiable"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,29]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20191188","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,5]]},"article-number":"BSR20191188"}}